Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec 18:2:110.
doi: 10.21037/tgh.2017.12.04. eCollection 2017.

Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma

Xavier Adhoute  1 , Paul Castellani  1 , Marc Bourlière  1
Affiliations
Editorial

Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma

Xavier Adhoute et al. Transl Gastroenterol Hepatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: X Adhoute: Grant from Bayer. M Bourlière: Board member (Merck-Schering Plough, Gilead, Janssen, Vertex, Boehringer - Ingelheim, BMS, Roche, Abbvie, GSK), speaker (Merck-Schering Plough, Gilead, Janssen, Vertex, Boehringer-Ingelheim, BMS, Roche, Abbvie, Novartis, GSK). P Castellani has no conflicts of interest to declare.

Comment on

References

    1. Global Burden of Disease Liver Cancer Collaboration , Akinyemiju T, Abera S, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 2017. [Epub ahead of print]. - PMC - PubMed
    1. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38. 10.1016/j.jhep.2006.05.013 - DOI - PubMed
    1. El-Serag HB, Kanwal F, Richardson P, et al. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016;64:130-7. 10.1002/hep.28535 - DOI - PMC - PubMed
    1. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98. 10.1056/NEJMoa1402454 - DOI - PubMed
    1. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82. 10.1056/NEJMoa1402869 - DOI - PubMed

LinkOut - more resources